Navigation Links
EuroPharma Exclusive Distributor of BCM-95 and BosPure
Date:12/16/2009

GREEN BAY, Wis., Dec. 16 /PRNewswire/ -- EuroPharma, Inc. signs exclusive multi-year contract with DolCas Biotech for the use of super absorbency BCM-95® curcumin and specialized BosPure® boswellia in multiple EuroPharma formulations. The exclusive distribution territory for these clinically-studied ingredients includes both the health food store channel and professional channel, which includes allopathic doctors, chiropractors, naturopathic doctors, and clinics. BCM-95® is a highly absorbable curcumin. Human clinical data indicates that BCM-95 is up to 10 times more absorbable than curcumin 95% and 6.3 times more absorbable than curcumin with lecithin and piperine. BosPure® boswellia is beta-boswellic acid free, and standardized to contain 10-15% AKBA (Acetyl-11-Keto-Beta-Boswellic Acid), which enhances its targeted impact on the body's natural anti-inflammatory response.

Currently, EuroPharma distributes unique formulations that contain a combination of BCM-95 and BosPure: Curamin®, Curacel(TM), Dyflaminol(TM) and Bos-Cur(TM). EuroPharma also distributes an all-curcumin product, CuraMed(TM), containing 750 mgs of BCM-95 phospholipid complex, which is equivalent to up to 7,500 mgs of curcumin 95%. Due to consumer demand, they have also created a softgel containing 375 mg dose (equivalent to up to 3,700 mgs of curcumin 95%).

Curamin has rapidly become the number one pain* relieving formula in America, and has won the 2009 VityAward as best new supplement on the market, and both the 2008 and 2009 Best of Supplements awards.

Dyflaminol is recommended for support of a healthy anti-inflammatory response. Bos-Cur is indicated for balancing healthy leukotrienes, which are signaling substances intimately involved in a healthy inflammatory response. Curacel, which also contains resveratrol and green tea polyphenols, is recommended for healthy cellular function, particularly for breast, prostate, uterus and ovaries.

EuroPharma has agreed to support the marketing, promotion and distribution of BCM-95 and BosPure formulas with a targeted multi-million-dollar marketing investment. Terry Lemerond, President and Founder of EuroPharma, recognized the impact that curcumin can have on world health.

"There is no better health solution for what's ailing the world than curcumin. It plays a powerful role as an immune enhancer, inflammatory response balancer, liver protector, and is a powerful antioxidant, having a reported ORAC value of 159,722 per one hundred grams. Those are incredible numbers. People in India refer to curcumin as the 'all-in-one solution', and I agree," states Lemerond.

EuroPharma and DolCas Biotech express the mutual goal of having a major impact on the health of the world. Working in partnership, they expect their efforts to greatly increase their ability to get clinically-studied, specialized products into the hands of the people who need them most.

"We are proud to enter into this agreement, not only because BCM-95 curcumin and BosPure boswellia are cutting-edge breakthroughs in supplement research, but because we are proud to represent such a fine partner in DolCas Biotech," states Lemerond.

K.G. Rao, founder of DolCas Biotech, adds, "We are extremely proud to enter into this agreement with EuroPharma and founder Terry Lemerond because of his 40 years experience in the health food industry and proven success in developing operations on retail, wholesale, and manufacturing sides. We are delighted to enter into this agreement because Lemerond has so thoroughly recognized the excellent benefits of BCM-95 and BosPure and has committed his company's resources to furthering the advancement of BCM-95 to health food retail and professionals."

Further research is being conducted on BCM-95 and BosPure and results will be published in the very near future.

*occasional pain due to exercise or overuse.

EuroPharma offers clinically proven and effective nutritional supplements and natural remedies that improve the health of America. Throughout his 40-year career, President and Founder Terry Lemerond has created more than 300 high-quality formulations, all backed by scientific validation. Many are unique, proprietary and, in some cases, patented. Lemerond was the first to introduce glucosamine sulfate, IP-6, black cohosh for menopause, and the concept of botanical standardization to the U.S. health food market. At EuroPharma, Our Passion is Your Health(TM). For more information on EuroPharma and its entire product line, visit www.EuroPharmaUSA.com.

DolCas Biotech, LLC is a progressive research and development organization with a mission is to introduce pioneering ingredients into the nutraceutical industry that will aid in the research of curing modern ailments in the most holistic, yet progressive, methods. DolCas Biotech aims to foster the development of every peak performing ingredient from inception to fruition. Each endeavor is supported with their own clinical research data, thus giving partners in the industry complete confidence.

SOURCE EuroPharma, Inc.


'/>"/>
SOURCE EuroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfenex Grants Exclusive License to Merck & Co., Inc. for the Production of Proteins for Undisclosed Vaccine Program
2. Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
3. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
4. Health Robotics Reaches 100% Asia-Pacific Coverage Through its New Exclusive Distribution Contract With BioRobotics in Korea
5. Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes
6. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
7. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
8. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
9. Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement
10. Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in Peoples Republic of China
11. Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016 Research and Markets has announced ... report to their offering. ... The global travel vaccines market to grow at a ... covers the present scenario and the growth prospects of the global ... report considers the revenue generated from the sales of various vaccines ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia Ophthalmic Lasers ... report, "Australia Ophthalmic Lasers Market Outlook to 2022", provides ... The report provides value, in millions of US dollars, ... segements - Excimer Lasers, Femtosecond Lasers and YAG Lasers. ... shares data for each of these market segements, and ...
(Date:12/8/2016)... KEY FINDINGS The global medical ... Various reasons for growth of the medical lifting sling ... chronic diseases, high recovery cost of injuries and government ... lifting sling refers to an assistive device that helps ... connect to the lift and hold the patient. It ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
(Date:12/8/2016)... , ... December 08, 2016 , ... CURE Media Group, ... and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung ... announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up ...
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... 08, 2016 , ... STAT courier is pleased to announce that due to ... they are expanding their presence in Dallas. One of the most exciting parts for ... jobs to the Dallas and Forth Worth market. STAT takes pride in treating their ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the ... Series B led by Canvas Ventures . Other investors include Nokia Growth Partners ... mobile platform to serve more consumers who are managing chronic conditions or ...
Breaking Medicine News(10 mins):